3 Stocks Raising The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 34 points (-0.2%) at 15,991 as of Tuesday, Dec. 10, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,256 issues advancing vs. 1,637 declining with 176 unchanged.

The Drugs industry currently sits down 0.7% versus the S&P 500, which is down 0.2%. A company within the industry that fell today was Sanofi ( SNY), up 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Incyte ( INCY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Incyte is up $1.84 (4.0%) to $47.99 on light volume. Thus far, 610,919 shares of Incyte exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $45.77-$48.40 after having opened the day at $46.35 as compared to the previous trading day's close of $46.15.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $7.5 billion and is part of the health care sector. Shares are up 177.8% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Incyte a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally high debt management risk. Get the full Incyte Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.29 (0.7%) to $40.44 on heavy volume. Thus far, 7.4 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 5.9 million shares. The stock has ranged in price between $40.20-$41.45 after having opened the day at $40.20 as compared to the previous trading day's close of $40.15.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $33.5 billion and is part of the health care sector. The company has a P/E ratio of 17.6, equal to the S&P 500 P/E ratio of 17.7. Shares are up 7.5% year to date as of the close of trading on Monday. Currently there are 5 analysts that rate Teva Pharmaceutical Industries a buy, 3 analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and weak operating cash flow. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Celgene Corporation ( CELG) is up $2.37 (1.4%) to $172.38 on average volume. Thus far, 1.1 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $170.50-$172.95 after having opened the day at $170.53 as compared to the previous trading day's close of $170.01.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $68.6 billion and is part of the health care sector. The company has a P/E ratio of 47.8, above the S&P 500 P/E ratio of 17.7. Shares are up 112.1% year to date as of the close of trading on Monday. Currently there are 19 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists